Skip to main content
    A

    Arcadia Biosciences Inc (RKDA)

    Official site

    CONSUMER DEFENSIVE • PACKAGED FOODS • NASDAQ

    $0.19
    -0.02 (-11.19%)

    Market Cap: $1.32M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Arcadia Biosciences Inc (RKDA) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Arcadia Biosciences (RKDA) trades at 0.2x sales and 0.5x book value. Its P/S of 0.2x is below its 5-year median of 0.9x. Its forward P/E is 36.6x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E36.6x
    Price to sales0.2x
    Price to book0.5x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 91.7% below 2.4x and its P/B is 54.5% below 1.1x.

    MultipleCurrent5-year median10-year median
    P/S0.2x0.9x2.4x
    P/B0.5x0.5x1.1x
    Medians of month-end values through Oct 2026: 54 to 59 months (5-year) and 104 to 105 months (10-year).

    Valuation History

    Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 0.6x in 2025 to 13.5x in 2018. 2025 was the lowest of those years.

    Year endPriceP/SP/B
    2025$1.980.6x0.7x
    2024$5.921.6x1.3x
    2023$3.130.8x0.3x
    2022$10.840.8x0.3x
    2021$41.603.3x0.7x
    2020$101.204.0x1.2x
    2019$219.20N/AN/A
    2018$126.8013.5x47.3x
    2017$220.002.9x1.5x
    2016$736.0012.8x1.8x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About RKDA

    What is RKDA's forward P/E ratio?

    Arcadia Biosciences has a forward P/E ratio of 36.6x.

    Is RKDA stock overvalued?

    GNG's valuation label for RKDA is Undervalued.

    What is RKDA's price to sales ratio?

    Arcadia Biosciences has a price to sales ratio of 0.2x.